Lapsi Health Company Profile

Background

Founded in 2021, Lapsi Health is a medical technology company headquartered in Amsterdam, Netherlands. The company specializes in developing sound-based medical technologies and software tools aimed at transforming the conventional use of auscultatory sounds in clinical medicine. By leveraging Finnish engineering and the expertise of healthcare professionals, Lapsi Health focuses on creating solutions that empower clinicians at the point of care and enhance remote consultations. Their mission is to harness the potential of sound to develop digital biomarkers, thereby improving patient outcomes and advancing healthcare practices.

Key Strategic Focus

Lapsi Health's strategic focus centers on the development of innovative auscultation technologies that convert physiological sounds into actionable digital biomarkers. Their core objectives include:

• Technology Development: Creating advanced hardware and software solutions for precise sound acquisition and analysis.

• Regulatory Compliance: Securing necessary certifications, such as FDA approval, to ensure product safety and efficacy.

• Market Expansion: Initiating commercialization activities, particularly targeting the U.S. healthcare market.

The company's primary markets include healthcare providers, patients, and researchers, with a particular emphasis on enhancing remote patient monitoring and telemedicine capabilities.

Financials and Funding

Since its inception, Lapsi Health has successfully secured multiple funding rounds to support its growth and development:

• Pre-Seed Round (March 2022): Raised €700,000 to initiate technology development and early-stage operations.

• Eurostars Grant (June 2022): Awarded a €1 million grant to advance deep tech development.

• Seed Round (January 2023): Closed an oversubscribed seed round of $3.7 million, led by Modi Ventures, with participation from existing investors Vendash and Bolwork, as well as new investor BeKey.

• Latest Funding (November 2024): Secured an additional $5.8 million to further technology development, obtain FDA certification, and commence commercialization activities in the U.S. market.

The capital raised is intended for continued technology development, regulatory approvals, and market entry strategies.

Pipeline Development

Lapsi Health's product pipeline includes:

• Keikku: A digital stethoscope designed for healthcare professionals, capable of capturing high-fidelity auscultatory sounds and converting them into digital biomarkers. Keikku received FDA Class II clearance and launched in the U.S. market with pre-orders and a robust pipeline of opportunities.

• Ilo: A wearable device aimed at pregnant women, designed to monitor fetal health by tracking the heartbeat and movements of the developing fetus. Ilo is currently under development, with plans for future regulatory approval and market introduction.

These products are at various stages of development, with Keikku already entering the commercialization phase and Ilo progressing through research and development.

Technological Platform and Innovation

Lapsi Health distinguishes itself through its proprietary technological platforms and innovative approaches:

• General Purpose Hardware Architecture (GPHA): A patented platform that integrates multiple sensors, including microphones, PPG sensors, accelerometers, gyroscopes, and proximity sensors, to capture comprehensive physiological data.

• Advanced Signal Processing Algorithms: Proprietary software algorithms process and analyze raw data to extract meaningful digital biomarkers, facilitating real-time health monitoring and diagnostics.

• AI-Driven Capabilities: The company is developing AI-based analysis features, such as heart murmur detection and respiratory condition monitoring, to enhance diagnostic accuracy and support clinical decision-making.

Leadership Team

Lapsi Health's leadership comprises experienced professionals with diverse backgrounds:

• Jhonatan Bringas Dimitriades, MD: Chief Executive Officer and Co-Founder. An expert in digital health and biomarkers, recognized as Health-tech Leader of the Year 2022 by Med-Tech World.

• Diana van Stijn, MD: Chief Medical Officer and Co-Founder. A leading expert in digital therapeutics and pediatrics, instrumental in developing the company's medical strategies.

• Seamus Holohan: Chief Operating Officer and Co-Founder. A seasoned entrepreneur with over 20 years of experience, responsible for overseeing operations and strategic initiatives.

• Rodrigo Alvez: Chief Technology Officer and Co-Founder. Brings extensive knowledge in software and app development, leading the technological advancements of the company.

The advisory board includes notable figures such as Craig Lipset, Rafael Grossman, Aline Noizet, Suzanne Terheggen, Carlos Sendon, Amir Lahav, and Junaid Bajwa, MD, Chief Medical Scientist at Microsoft, providing strategic guidance and industry insights.

Leadership Changes

In the last quarter of 2022, Lapsi Health welcomed Junaid Bajwa, MD, Chief Medical Scientist at Microsoft, to its advisory board, enhancing the company's med-tech expertise and accelerating development efforts.

Competitor Profile

Market Insights and Dynamics

The digital health market is experiencing significant growth, driven by advancements in technology and increasing demand for remote patient monitoring solutions. The global digital stethoscope market, in particular, is expanding as healthcare providers seek more accurate and efficient diagnostic tools.

Competitor Analysis

Key competitors in the digital stethoscope and remote patient monitoring space include:

• Eko Health: Offers digital stethoscopes with AI-powered analysis for heart and lung sounds, focusing on enhancing cardiac and pulmonary diagnostics.

• Thinklabs Medical: Provides electronic stethoscopes with high-fidelity sound quality, catering to healthcare professionals seeking advanced auscultation tools.

• 3M Littmann: A well-established brand offering electronic stethoscopes with amplification and noise reduction features, widely used in clinical settings.